213 related articles for article (PubMed ID: 25811617)
1. TOX acts an oncological role in mycosis fungoides.
Yu X; Luo Y; Liu J; Liu Y; Sun Q
PLoS One; 2015; 10(3):e0117479. PubMed ID: 25811617
[TBL] [Abstract][Full Text] [Related]
2. Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.
Mehdi SJ; Moerman-Herzog A; Wong HK
BMC Cancer; 2021 May; 21(1):492. PubMed ID: 33941102
[TBL] [Abstract][Full Text] [Related]
3. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
4. Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis.
Huang Y; Litvinov IV; Wang Y; Su MW; Tu P; Jiang X; Kupper TS; Dutz JP; Sasseville D; Zhou Y
Oncotarget; 2014 Jun; 5(12):4418-25. PubMed ID: 24947046
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers of early-stage mycosis fungoides.
Zhang Y; Wang Y; Yu R; Huang Y; Su M; Xiao C; Martinka M; Dutz JP; Zhang X; Zheng Z; Zhou Y
J Invest Dermatol; 2012 Jun; 132(6):1698-706. PubMed ID: 22377759
[TBL] [Abstract][Full Text] [Related]
6. TOX Outperforms FOXP3, CD4 and GATA3 in Histopathological Diagnosis of Early Mycosis Fungoides.
Ahmed MM; Hegazy AA; Embaby A; Nawwar EM; Hegazy SA; Ibrahim HM; Gobran MA
Turk Patoloji Derg; 2023; 39(1):15-22. PubMed ID: 35642346
[TBL] [Abstract][Full Text] [Related]
7. Thymocyte selection-associated high-mobility group box as a potential diagnostic marker differentiating hypopigmented mycosis fungoides from early vitiligo: A pilot study.
Ibrahim MA; Mohamed A; Soltan MY
Indian J Dermatol Venereol Leprol; 2021; 87(6):819-825. PubMed ID: 31857520
[TBL] [Abstract][Full Text] [Related]
8. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation.
Hu SC; Lin CL; Hong CH; Yu HS; Chen GS; Lee CH
J Dermatol Sci; 2014 Apr; 74(1):31-8. PubMed ID: 24411580
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides with epidermal mucinosis: a variant of mycosis fungoides with a spongiosis-like pattern.
Hu SW; Ratech H; Naeem R; Latkowski JA; Kamino H
J Cutan Pathol; 2015 Oct; 42(10):730-8. PubMed ID: 26009972
[TBL] [Abstract][Full Text] [Related]
10. The Value of Immunohistochemical Expression of TOX, ICOS, and GATA-3 in the Diagnosis of Mycosis Fungoides.
Atwa HA; Abdelrahman DI
Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):163-171. PubMed ID: 36805367
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils in mycosis fungoides: an uncommon finding in the patch and plaque stages.
Dalton SR; Chandler WM; Abuzeid M; Hossler EW; Ferringer T; Elston DM; LeBoit PE
Am J Dermatopathol; 2012 Aug; 34(6):586-91. PubMed ID: 22814317
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD31 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Grzegrzolka J; Piotrowska A; Gomulkiewicz A; Glatzel-Plucinska N; Olbromski M; Podhorska-Okolow M; Szepietowski JC; Dziegiel P
Anticancer Res; 2016 Sep; 36(9):4575-82. PubMed ID: 27630298
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications.
Alcántara-Hernández M; Torres-Zárate C; Pérez-Montesinos G; Jurado-Santacruz F; Domínguez-Gómez MA; Peniche-Castellanos A; Ferat-Osorio E; Neri N; Nambo MJ; Alvarado-Cabrero I; Moreno-Lafont M; Huerta-Yepez S; Bonifaz LC
Int J Cancer; 2014 May; 134(9):2136-45. PubMed ID: 24127318
[TBL] [Abstract][Full Text] [Related]
14. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of BCL11B in mycosis fungoides and its potential role in interferon-induced apoptosis.
Gu X; Wang Y; Zhang G; Li W; Tu P
J Dermatol; 2013 Aug; 40(8):596-605. PubMed ID: 23682716
[TBL] [Abstract][Full Text] [Related]
18. The expression of CXCR3 and CD30 in mycosis fungoides.
Nikoo A
Arch Iran Med; 2012 Mar; 15(3):146-50. PubMed ID: 22369302
[TBL] [Abstract][Full Text] [Related]
19. TOX, TWIST1, STAT4, and SATB1 protein expressions in early-stage mycosis fungoides.
Örnek S; Ozekinci S; Ipin T; Kocaturk E
J Cutan Pathol; 2024 Mar; 51(3):232-238. PubMed ID: 37932931
[TBL] [Abstract][Full Text] [Related]
20. TOX expression and role in CTCL.
McGirt LY; Degesys CA; Johnson VE; Zic JA; Zwerner JP; Eischen CM
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1497-502. PubMed ID: 27345620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]